This Week in HIV Research: Exorcizing Our PrEP Demons

This Week in HIV Research: Exorcizing Our PrEP Demons

1 of 5
Next >

We've got a new group of studies to highlight this week that may well spur some soul-searching. If none of them do so, that's probably because you're already among the converted -- and if they do, consider sharing the findings with your colleagues, patients, and clients, to keep the conversation flowing.

There's a new reckoning underway in our thinking about some aspects of the continuing HIV epidemic, as evidenced by some of these featured papers:

  • A multidisciplinary group of experts pushes for normalization of pre-exposure prophylaxis (PrEP) in a major medical journal.
  • A new Centers for Disease Control (CDC) report finds that the vast preponderance of U.S. HIV transmissions occur among people with HIV who are not in care.
  • A Swiss study dives into potential factors associated with HIV drug resistance -- and finds that sociodemographic disadvantages may be at the core.
  • A real-world analysis of integrase inhibitor use among treatment-experienced people finds high success rates -- but only among those who had no baseline viremia.

Come along and free your spirit with a closer look at each of these peer-reviewed manuscripts. To beat HIV, you have to follow the science!

Myles Helfand is the executive editor and general manager of TheBody and TheBodyPRO. Follow Myles on Twitter: @MylesatTheBody.

Image Credit: CasPhotography for iStock via Thinkstock

We've got a new group of studies to highlight this week that may well spur some soul-searching. If none of them do so, that's probably because you're already among the converted -- and if they do, consider sharing the findings with your colleagues, patients, and clients, to keep the conversation flowing.

There's a new reckoning underway in our thinking about some aspects of the continuing HIV epidemic, as evidenced by some of these featured papers:

  • A multidisciplinary group of experts pushes for normalization of pre-exposure prophylaxis (PrEP) in a major medical journal.
  • A new Centers for Disease Control (CDC) report finds that the vast preponderance of U.S. HIV transmissions occur among people with HIV who are not in care.
  • A Swiss study dives into potential factors associated with HIV drug resistance -- and finds that sociodemographic disadvantages may be at the core.
  • A real-world analysis of integrase inhibitor use among treatment-experienced people finds high success rates -- but only among those who had no baseline viremia.

Come along and free your spirit with a closer look at each of these peer-reviewed manuscripts. To beat HIV, you have to follow the science!

Myles Helfand is the executive editor and general manager of TheBody and TheBodyPRO. Follow Myles on Twitter: @MylesatTheBody.

Image Credit: CasPhotography for iStock via Thinkstock